INS and metabolic dysfunction-associated steatotic liver disease: Upregulating the expression of peroxisome proliferator activated receptor γ (PPARγ), insulin receptor mRNA, and protein in liver tissue, and significantly reducing tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), to exert effects of reducing insulin resistance, regulating fat metabolism, improving liver function, and inhibiting liver inflammation in NAFLD.